At HaploX, we believe genomic innovation should not only advance healthcare, but also create long-term value for patients, healthcare providers, researchers, pharmaceutical partners, and communities.
As a genomic technology company, HaploX integrates sustainability principles into our operations, scientific collaborations, and business practices.
Through trusted genomic science, responsible innovation, and sustainable operations, we strive to contribute to a healthier future.
Our Sustainability Commitment
Sustainability is an integral part of HaploX’s long-term development.
Our sustainability priorities focus on four key areas where we can create meaningful impact: advancing healthcare innovation, ensuring responsible genomic practices, operating sustainably, and empowering our people.
We are committed to:
Advancing precision healthcare through genomic innovation;
Supporting biomedical research and therapeutic development;
Ensuring responsible management and ethical use of genomic data;
Maintaining high standards of quality, compliance, and scientific integrity;
Building a safe, inclusive, and innovative workplace;
Continuously improving the sustainability of our operations.
Through responsible practices and continuous improvement, we aim to create lasting value for patients, partners, and communities.
Healthcare & Scientific Impact
HaploX leverages advanced genomic technologies and bioinformatics capabilities to support healthcare providers in delivering more precise and personalized healthcare solutions.
Our genomic solutions enable:
Earlier disease detection;
More accurate diagnosis;
Personalized treatment decisions;
Improved disease management.
Through precision oncology and genomic medicine, HaploX helps clinicians better understand diseases and make informed healthcare decisions.
We are committed to expanding the applications of genomic testing and supporting broader adoption of precision medicine to address evolving clinical needs worldwide.
Beyond clinical applications, HaploX supports academic institutions and research organizations with comprehensive multi-omic testing services and advanced analytical capabilities.
We collaborate with researchers to:
Drive multi-omic discoveries;
Support large-scale multi-omic studies;
Accelerate translational research with integrated omics data.
By delivering reliable, multi-layered omics insights, HaploX fuels scientific progress and innovation across the life sciences.
HaploX collaborates with pharmaceutical companies to support biomarker discovery, translational research, and clinical development.
Our genomic capabilities support:
Biomarker identification;
Clinical research programs;
Precision medicine development;
Data-driven insights for therapeutic innovation.
Through collaboration with healthcare and life science partners, HaploX helps accelerate the translation of genomic discoveries into clinical applications.
Trusted Science & Responsible Governance
HaploX has established ESG governance mechanisms to support responsible decision-making, risk management, and continuous improvement.
ESG-related strategies and initiatives are overseen through dedicated governance structures to ensure effective implementation, accountability, and continuous enhancement of our sustainability practices.
We work with partners who share our commitment to responsible and sustainable practices.
Genomic information provides valuable insights into human health and requires responsible management.
HaploX is committed to:
Protecting patient privacy;
Ensuring secure genomic data management;
Applying ethical principles in genomic applications;
Maintaining responsible sample and data handling practices.
We continuously strengthen our governance framework to ensure genomic information is managed securely, ethically, and responsibly throughout the testing and research process.
Quality and scientific integrity are fundamental to HaploX’s commitment to trusted genomic solutions.
We maintain rigorous quality management systems to ensure accuracy, reliability, and consistency across our genomic testing services.
Our commitment to international quality standards is supported by:
CAP-accredited laboratory operations
CLIA certification
EMQN participation in external quality assessment programs
ISO 13485 certification
Through continuous quality improvement and adherence to international standards, HaploX strives to deliver reliable genomic insights for healthcare providers, researchers, and partners worldwide.
Public Welfare
HaploX runs public-interest Alzheimer's screening and education across Shenzhen communities. Our initiatives include:
Offered 10 free clinical breast-cancer gene tests to patients nationwide, supporting women's precision care through genetic technology.
Through genetic technology, HaploX practices CSR via "tech for good."
People & Culture
Our people are the foundation of scientific innovation.
HaploX is committed to fostering a workplace that supports:
Professional development;
Scientific learning;
Health and safety;
Diversity, inclusion, and collaboration.
By empowering our employees, we continue to advance genomic innovation and healthcare progress.
HaploX maintains workplace health and safety practices designed to protect employees and support safe laboratory operations.
Our initiatives include:
Workplace safety guidelines;
Regular safety inspections;
Emergency response procedures;
Laboratory risk management.
We have maintained a strong safety record, with zero reported workplace accidents in the past three years. We remain committed to maintaining a safe and responsible working environment for all employees.
HaploX promotes a vibrant workplace and encourages marathon and endurance sports.
Our initiatives include:
Hosting employee running carnivals and marathons;
Offering fitness assessments and training guidance to participants.
This sports culture boosts employees' vitality and team cohesion.
Looking Forward
HaploX will continue integrating sustainability principles into our journey of genomic innovation.
By combining advanced genomic technologies with responsible practices, we aim to create lasting value for patients, healthcare providers, researchers, pharmaceutical partners, employees, and communities.
Together, we advance human health through responsible genomic innovation.
